Alternative And Conventional Biomedical Research: A Creative Synergy

Editor's Note: This first part of a two-part series charts the shared ground between research into alternative medical therapies and basic biomedical research. Increasingly, researchers are using powerful cellular and molecular tools to uncover biochemical pathways that may, for example, explain increasingly evident mind-body connections in health and illness. The second part, to appear in the March 21 issue, will explore efforts t

Written byFranklin Hoke
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

Despite tight budgeting in many sectors of biomedical research, the fledgling Office of Alternative Medicine (OAM) at the National Institutes of Health recently learned it is slated for a big financial uplift.

In each of its first two years of existence, 1992 and 1993, the office received $2 million; for fiscal year 1994, however, President Bill Clinton requested and received $3.5 million.

Although just a "drop in the bucket" of NIH's $11 billion overall budget, as OAM spokesman Jim Bryant notes, it is still a significant and symbolic increase for the young, high-profile office--likely to mean more money for grants.

The jump in funding at OAM is indicative of the rising interest in and support for research in alternative medicine in many established biomedical settings, according to scientists and officials. Teaching programs also are in place or planned at several top medical schools. The establishment of such programs suggests that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies